Antidepressants in clinical practice

Author/s
Mark Agius, Hanna Bonnici
Citation
Issue 5 Winter 2018
CEPiP.2018.1.55-63
Abstract

The objective of this paper, rather than to provide new information, is to produce a vademecum for doctors prescribing antidepressants, including useful information for when they are being prescribed. Antidepressants should be seen as part of a package of treatment for the patient with depression. This package also should include psychological treatments and social interventions. Here the main antidepressant groups, including the selective serotonin reuptake inhibitors, the tricyclics and other classes are described, together with their mode of action, adverse effects and dosages. Antidepressants should usually be prescribed for six months. The efficacy of antidepressants is similar between classes, despite their different mechanisms of action. The choice is usually based on avoiding adverse effects, or sometimes on beneficial side effects. No single antidepressant is beneficial without any adverse effects. Increasing knowledge of what exactly causes depression should enable researchers not only to create more effective antidepressants rationally, but also to understand the limitations of existing drugs.

Keywords: antidepressants, depression, psychological therapies, social therapies

Cite as: Cutting Edge Psychiatry in Practice 2018, 5(1):55-63; https://doi.org/10.65031/laje7878

References

  1. Azzopardi LM. Lecture notes in pharmacy practice: Pharmaceutical Press; 2009                
  2. Fekadu N, Shibeshi W, Engidawick E. Major depressive disorder: pathophysiology and clinical management. Journal of Depression and Anxiety 2016;6:255 https://doi.org/10.4172/2167-1044.1000255
  3. Joint Formulary Committee. British National Formulary. 75th ed. London: BMJ Group and Pharmaceutical Press; 2018        
  4. Feighner JP. Mechanism of action of antidepressant medications. The Journal of Clinical Psychiatry. 1999;60:4-11               
  5. Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. The British Journal of Psychiatry. 1994 Apr;164(4):549-50 https://doi.org/10.1192/bjp.164.4.549
  6. Safety bulletin: dosulepin prescribing [Internet]. NHS Dorset Clinical Commissioning Group; 2016 [cited 17 December 2018]. Available from: https://www.dorsetccg.nhs.uk/Downloads/aboutus/medicines-management/ Other%20Guidelines/2016_17%20-%20Safety%20bulletin%20Dosulepin.pdf
  7. Rihmer Z, Gonda X. The effect of pharmacotherapy on suicide rates in bipolar patients. CNS Neuroscience & Therapeutics. 2012 Mar;18(3):238-42 https://doi.org/10.1111/j.1755-5949.2011.00261.x
  8. El-Mallakh RS, Vöhringer PA, Ostacher MM, Baldassano CF, Holtzman NS, Whitham EA, Thommi SB, Goodwin FK, Ghaemi SN. Antidepressants worsen rapid-cycling course in bipolar depression: a STEP-BD randomized clinical trial. Journal of Affective Disorders. 2015 Sep 15;184:318-21 https://doi.org/10.1016/j.jad.2015.08.015
  9. Rihmer Z, Rihmer A, Döme P. Suicidal behaviour in patients with mood disorders. Evidence-Based Psychiatric Care. 2015;1:19-26        
  10. Rihmer Z, Gonda X. Pharmacological prevention of suicide in patients with major mood disorders. Neuroscience & Biobehavioral Reviews. 2013 Dec 1;37(10):2398-403 https://doi.org/10.1016/j.neubiorev.2012.09.009
  11. Woodland G. What is the risk of gastrointestinal bleeding associated with selective serotonin reuptake inhibitors (SSRIs)? SPS - Specialist Pharmacy Service. The first stop for professional medicines advice [Internet]. Sps.nhs.uk. 2015 [cited 14 January 2019]. Available from: https://www.sps.nhs.uk/articles/what-is-the-risk-of-gastrointestinal-bleeding-associated-with-selective-serotonin-reuptake-inhibitors-ssris/ https://doi.org/10.1211/cp.2013.11120683
  12. Weintraub D, Mavandadi S, Mamikonyan E, Siderowf AD, Duda JE, Hurtig HI, Colcher A, Horn SS, Nazem S, Ten Have TR, Stern MB. Atomoxetine for depression and other neuropsychiatric symptoms of Parkinson disease. Neurology. 2010 Aug 3;75(5):448-55 https://doi.org/10.1212/wnl.0b013e3181ebdd79
  13. Patel R, Reiss P, Shetty H, Broadbent M, Stewart R, McGuire P, Taylor M. Do antidepressants increase the risk of mania and bipolar disorder in people with depression? A retrospective electronic case register cohort study. BMJ Open. 2015 Dec 1;5(12):e008341 https://doi.org/10.1136/bmjopen-2015-008341
  14. Fagiolini A, Comandini A, Dell'Osso MC, Kasper S. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs. 2012 Dec 1;26(12)1033-49 https://doi.org/10.1007/s40263-012-0010-5
  15. Manikandan S. Agomelatine: A novel melatonergic antidepressant. Journal of Pharmacology & Pharmacotherapeutics. 2010 Jul;1(2):122 https://doi.org/10.4103/0976-500x.72369